Formycon AG
Formycon AG, a biotechnology company, develops biosimilar drugs in Germany and Switzerland. It provides ranibizumab and aflibercept used in the treatment of neovascular age-related macular degeneration, diabetic macular edema, choroidal neovascularization, proliferative diabetic retinopathy, and macular edema under the Ranivisio, Ongavia, Cimerli, Ranopto, Uptera, and Ravegza brand names, as well… Read more
Formycon AG (FYB) - Total Liabilities
Latest total liabilities as of June 2025: €334.23 Million EUR
Based on the latest financial reports, Formycon AG (FYB) has total liabilities worth €334.23 Million EUR as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Formycon AG - Total Liabilities Trend (2009–2024)
This chart illustrates how Formycon AG's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Formycon AG Competitors by Total Liabilities
The table below lists competitors of Formycon AG ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TLB Co. Ltd.
KQ:356860
|
Korea | ₩104.05 Billion |
|
Enity
ST:ENITY
|
Sweden | Skr32.79 Billion |
|
CoAsia Microelectronics
TWO:8096
|
Taiwan | NT$5.91 Billion |
|
Almonty Industries Inc
OTCQX:ALMTF
|
USA | $305.14 Million |
|
Suzhou Jin Hong Shun Auto Parts Co Ltd Class A
SHG:603922
|
China | CN¥305.98 Million |
|
Friend Co Ltd
SHG:605050
|
China | CN¥4.13 Billion |
|
Tianjin Tianyao Pharmaceuticals Co Ltd
SHG:600488
|
China | CN¥1.85 Billion |
|
Guangdong Chant Group Inc
SHE:002616
|
China | CN¥7.51 Billion |
Liability Composition Analysis (2009–2024)
This chart breaks down Formycon AG's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.54 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.67 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.45 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Formycon AG's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Formycon AG (2009–2024)
The table below shows the annual total liabilities of Formycon AG from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €309.87 Million | -20.06% |
| 2023-12-31 | €387.61 Million | -22.03% |
| 2022-12-31 | €497.12 Million | +3253.46% |
| 2021-12-31 | €14.82 Million | +96.00% |
| 2020-12-31 | €7.56 Million | +41.51% |
| 2019-12-31 | €5.34 Million | -16.28% |
| 2018-12-31 | €6.38 Million | +20.82% |
| 2017-12-31 | €5.28 Million | +23.03% |
| 2016-12-31 | €4.29 Million | +88.68% |
| 2015-12-31 | €2.28 Million | -30.28% |
| 2014-12-31 | €3.26 Million | +2.22% |
| 2013-12-31 | €3.19 Million | -5.48% |
| 2012-12-31 | €3.38 Million | +639.50% |
| 2011-12-31 | €457.00K | +118.40% |
| 2010-12-31 | €209.25K | +243.03% |
| 2009-12-31 | €61.00K | -- |